Begin main content

RFA: Inlyta for Metastatic Renal Cell Carcinoma

Project Number pCODR RFA 0001
Brand Name Inlyta
Generic Name Axitinib
Tumour Type Genitourinary
Indication Metastatic Renal Cell Carcinoma
Funding Request RFA Question from the Provincial Advisory Group Is there evidence to fund axitinib as an alternative to everolimus for the second-line treatment of metastatic clear cell renal carcinoma?
Review Status Open for Input on Request for Advice
Pre Noc Submission
NOC Date
Manufacturer Pfizer Canada Inc.
Submitter pCODR Provincial Advisory Group
Submission Date April 18, 2017
Submission Type Request for Advice
Prioritization Requested
Stakeholder Input Deadline ‡ May 2, 2017
Check-point meeting (target date)
pERC Meeting (target date) June 15, 2017
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.